Reflecting growing concern over the opioid crisis, Walgreens Boots Alliance (WBA) shareholders voted in favor of a proposal calling for the company to issue a regular report on how it manages the risk of distributing these addictive prescription painkillers, according to preliminary results.

The proposal requires the pharmacy chain to prepare a report by June 30 detailing any changes the company has made to corporate governance since 2012 concerning opioid sales. The report should include specific board oversight of programs pertaining to opioids and whether and how executive compensation has been changed to reflect incentives.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy